

Lipid management in Diabetes (see [APC advice](#))

<p>To improve the lipid profile to:</p> <ul style="list-style-type: none"> • Reduce the risk of cardiovascular disease • Reduce the risk of pancreatitis in patients with severe hypertriglyceridaemia 	<p>NICE recommended targets</p> <p>Total Cholesterol < 4 mmol/l or LDL-C <2 mmol/l (NICE CG66 and CG67 May 2008)</p>
--	---

Lifestyle The importance of expert dietary advice, weight reduction, limiting alcohol consumption, exercise and smoking cessation should be emphasised and continually monitored.

Primary Prevention	
<p>Type 1 diabetes</p> <ul style="list-style-type: none"> • Consider statin treatment for primary prevention of CVD in all adults with type 1 diabetes. • Offer statin treatment to patients who: <ul style="list-style-type: none"> ○ Are >40 years of age ○ Have had diabetes for >10 years ○ Have established nephropathy ○ Have other CVD risk factors <p><u>First line statin choice</u> Atorvastatin 20mg od</p>	<p>Type 2 diabetes</p> <ul style="list-style-type: none"> • Use QRISK2 risk assessment tool to assess CVD risk. • Offer statin to patients with a 10% or greater 10-year risk of developing CVD. <p><u>First line statin choice</u> Atorvastatin 20mg od</p>
For all patients (primary or secondary prevention) started on a high intensity statin (atorvastatin 20mg od and above)	
<ul style="list-style-type: none"> • Measure total cholesterol, HDL cholesterol, non-HDL cholesterol at 3 months in all patients started on a high intensity statin. • Aim for a 40% reduction in non-HDL. If not achieved: <ul style="list-style-type: none"> ○ Discuss adherence and timing of dose ○ Optimise adherence to diet and lifestyle measures ○ Consider increasing the dose if patient taking a lower dose than 80mg atorvastatin and person judged to be at high risk due to comorbidities, risk score or using clinical judgement. 	

<p>Elevated Triglycerides (fasting lipid profile)</p> <p>Assess and manage secondary causes of high triglycerides:</p> <ul style="list-style-type: none"> • Poor blood glucose • Hypothyroidism • Renal impairment • Liver inflammation particularly from alcohol. • If Triglyceride remain > 5.7 (based on ADA standards of care 2020)mmol/l consider fibrate (first choice fenofibrate) either before or in addition to statin (the risk of pancreatitis is increased especially if Triglyceride is > 10 mmol/l). • Nicotinic acid or derivatives: Do not use routinely. May be considered if intolerance to statins or fenofibrate. • Omega-3-fish oils: Do not use in primary prevention of CVD (unless as part of specialist treatment of hypertriglyceridaemia). 	<p>Samples</p> <ul style="list-style-type: none"> • There is no post prandial rise in total and LDL-cholesterol • A non-fasting sample is suitable for initial screening only. • A fasting sample should be obtained if triglyceride is significantly raised.
---	---

<p>Referral to specialist care should be considered:</p> <ul style="list-style-type: none"> • If control remain poor • Severe mixed hyperlipidaemia, with triglycerides >4.5 mmol/l • When combination therapy is necessary • If there is concern about liver function tests and the advisability of starting a statin • If there is a family history of premature cardiovascular disease and familial hypercholesterolaemia • If there is drug intolerance
